Botulinum Toxin for Raynaud Phenomenon in Systemic Sclerosis: What the Research Says
For people living with systemic sclerosis (SSc)—a chronic autoimmune disease that thickens skin and damages blood vessels—Raynaud phenomenon (RP) is often a painful, disabling reality. Up to 90% of SSc patients develop RP, which triggers sudden vasospasms: narrowing of small blood vessels in the fingers or toes that causes color changes (white → blue → red), intense pain, and even non-healing digital ulcers (DUs). Conventional treatments—like keeping warm, calcium channel blockers, or surgery—don’t always stop the spasms or heal ulcers. Could botulinum toxin (BTX), best known for reducing wrinkles, offer relief?
What Is Raynaud Phenomenon in Systemic Sclerosis?
RP is a symptom, not a disease. In SSc, it’s “secondary” RP—driven by the disease’s damage to tiny blood vessels. Unlike primary RP (which affects healthy people), SSc-related RP is often more severe, longer-lasting, and linked to complications like non-healing ulcers. For many patients, it’s not just uncomfortable—it’s disabling, making it hard to hold a cup, type, or perform daily tasks.
Could Botulinum Toxin Help? A 2022 Review Breaks It Down
A 2022 systemic review published in the Chinese Medical Journal by researchers from Peking University Third Hospital’s Department of Rheumatology and Immunology (Ruyi Cai, Zixi Yi, Ting Li, and Rong Mu) analyzed five clinical studies to explore BTX’s role in treating SSc-related RP. The review included 155 patients who’d failed standard treatments—giving us a clear look at whether BTX works, how it’s used, and who might benefit.
What the Studies Tested: BTX Types, Doses, and Injection Sites
Botulinum toxin works by blocking nerve signals that cause muscle contraction or blood vessel spasms. The review focused on two types used for RP:
- BTX-A: The most common type (used in products like Botox). Studies tested doses from 10 to 100 units.
- BTX-B: A less potent type. Doses ranged from 250 to 2000 units (higher than BTX-A because it’s weaker per unit).
Injection sites varied:
- Palmar (palm) injection: Targeted “neurovascular bundles”—groups of nerves and blood vessels in the hand. Used in three studies.
- Dorsal (back of hand) injection: Near the base of the finger bones. Used in two studies.
Does BTX Work for SSc-Related RP?
For many patients, yes. Four out of five studies found BTX improved symptoms:
- Reduced pain and RP severity: A 2016 study by Motegi et al found BTX-A lowered RP scores (measuring frequency, pain, color changes, and duration) and pain ratings (via a Visual Analogue Scale/VAS). Skin temperature recovery after cold exposure—an indicator of blood flow—also improved.
- Healed ulcers: A 2014 study by Uppal et al reported 75% of patients with finger ulcers had complete healing after BTX-A injections.
- Better hand function: Uppal’s study also found improved hand movement and function—critical for daily life.
- BTX-B works too: A 2017 RCT by Motegi et al found BTX-B (1000–2000 units) reduced ulcer counts and improved symptoms, similar to BTX-A but at higher doses.
One study didn’t find a significant benefit: A 2017 double-blind RCT by Bello et al tested BTX-A in 40 patients and found only small, non-statistically significant improvements. The team noted two key factors: patients with longer RP duration (>15 years) or diffuse SSc (a more severe subtype with widespread skin thickening) were less likely to respond.
Who Might Benefit (and Who Might Not)
BTX is most promising for:
- Patients with severe, treatment-resistant SSc-related RP (failed meds/surgery).
- Those with limited SSc (a milder subtype affecting mostly the hands/face) or shorter RP duration (<15 years).
- Patients open to palmar injections (studies suggest these work better than dorsal injections).
Who might not benefit as much?
- Patients with diffuse SSc or RP lasting over 15 years.
- Those seeking a “permanent cure”—effects last 4–6 months, so repeat injections are needed.
What This Means for Patients
For people with SSc-related RP, BTX isn’t a first-line treatment—but it’s a valuable option when other methods fail. The review’s findings are hopeful, but they also remind us to be realistic: BTX won’t work for everyone, and more research is needed to confirm the best doses, injection sites, and patient subgroups.
If you’re considering BTX, talk to your rheumatologist or hand specialist. They can help you weigh the benefits (pain relief, ulcer healing) against mild side effects (temporary hand weakness, injection-site pain) and whether you’re a good candidate.
The original review was published in the Chinese Medical Journal in 2022 (Cai R, Yi Z, Li T, Mu R). You can access the full study via its DOI: doi.org/10.1097/CM9.0000000000001903
Was this helpful?
0 / 0